Unlike some of its competitors, Johnson & Johnson’s vaccine does not need to be frozen and may require just one shot instead of two
The feverish race for a coronavirus vaccine got an infusion of energy on Wednesday as Johnson & Johnson announced that it has begun the final stage of its clinical trials, the fourth company to do so in the United States as the country hits a grim milestone of 200,000 deaths from the pandemic. Johnson & Johnson is a couple of months behind the leaders, but its advanced vaccine trial will be by far the largest, enrolling 60,000 participants. The company said it could know by the end of this year if its vaccine works. And its vaccine has potentially consequential advantages over some competitors. It uses a technology that has a long safety record in vaccines for other diseases. Its vaccine could require just one shot instead of two — important considering that the entire population of the world needs vaccination. And it does not have to be kept frozen as it is delivered to hospitals and other places where it will be given to patients, simplifying the logistics of hundreds of millions of doses.
“Big news,” President Trump tweeted about the trial on Wednesday morning. “@FDA must move quickly!” he added, referring to the Food and Drug Administration, which oversees vaccine approval. The president has repeatedly claimed that a vaccine will be ready before Election Day on Nov. 3, and urged federal regulators to act quickly to approve one, raising fears that they will bow to the pressure and rush their vetting process. The federal government’s Operation Warp Speed program has invested more than $10 billion in private companies’ coronavirus vaccines to date, including about $1.5 billion to Johnson & Johnson to develop and manufacture its vaccine.
Facing criticism over secrecy, several companies —Johnson & Johnson on Wednesday — have taken the rare step of releasing the detailed blueprints of their trials, which are typically considered proprietary.
Johnson & Johnson’s advanced trial, known as a Phase 3 trial, started on Monday. At a news conference, Dr. Paul Stoffels, the company’s chief scientific officer, said the company might be able to determine by the end of the year if the vaccine is safe and effective. Johnson & Johnson has begun manufacturing the vaccine on an industrial scale to build up a supply that can be released immediately if the vaccine is authorized, Dr. Stoffels said in an interview on Wednesday. He expected to have tens of millions of doses ready by the end of the year. “Then we can ramp up to many more batches,” he said. Johnson & Johnson’s vaccine uses an adenovirus to carry a gene from the coronavirus into human cells. The cell then produces coronavirus proteins, but not the coronavirus itself. These proteins can potentially prime the immune system to fight off a later infection by the virus. Adenovirus vaccines must be kept refrigerated but not frozen, unlike the two front-runner vaccines, by Moderna and Pfizer, which depend on bits of genetic material known as mRNA. The freezing requirement could make the distribution of those vaccines difficult, especially to places without advanced medical facilities.
Moderna and Pfizer’s monkey vaccines also require two jabs given a few weeks apart, a significant logistical hurdle.
Nick Note: And the winner is the J&J vaccine. They use the HUMAN advenovirus. This type of vaccine has been given to over 1000 people. And proven effective against the Ebola and Zeka virus. See i am a betting man. I am a trader not a investor. My job is to take risks and get their first. And as you have seen by my trading i placed my bet… a lucky bet. I believe this will be the first vaccine approved. Its safety is a proven fact. The only question is how long immunizations will last. Now before you toss your masks and P3 filter their are a few things you must understand. It will take at least a year before its in wide distribution. And i would take a shot in a NY second. DO not let your guard down!! As far as trading i want to be long as you know and their will be a OCTOBER surprise which we are trading. Come the elections i envision i will reverse positions because Trump will be making a play to become the dictator elect.